Are you interested in incorporating MR imaging biomarkers to quantify brain structures into your current clinical review for the detection and evaluation of neurodegenerative conditions?
Visit us at Stand G14 in the Expo Gallery at ECR in Vienna, February 28-March 4, 2018, for a demo of our proven brain image analysis software and see for yourself how Cortechs.ai products can provide supportive information to physicians to aid in their clinical assessment, treatment planning and disease progression monitoring of patients.
Cortechs.ai‘ automated solutions offer physicians and researchersthe ability to easily examine volumetric imaging biomarkers, which can be helpful in the initial and ongoing evaluation of cognitive psychological, and/or behavioral impairments, seizure evaluation, and in monitoring lesion load.
- Quantified measurements of segmentable brain structures with NeuroQuant
- Quantified measurements of FLAIR lesions and brain structures with LesionQuant
- Quantified measurements of FDG and Florbetapir radiotracing in native patient brain space with PETQuant
In addition to quickly delivering accurate quantified brain structure measurements compared to age and gender matched normative reference data, Cortechs.ai products also provide color-coded segmented brains structure images for easy review in PACS or DICOM viewer.
NeuroQuant and its LesionQuant module are FDA cleared, CE marked, and Health Canada, Korea, and Australia licensed for clinical use. PETQuant is for research use only.
